Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

The primary objective of this study is to demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) against 3 N. meningitidis serogroup B reference strains (H44/76, 5/99, and NZ98/254) and as measured by ELISA geometric mean concentrations (GMCs) against vaccine antigen 287-953, approximately 30 days after a primary vaccination course of two doses administered one month apart.

Study Overview

• Status: Completed
• Conditions: Meningococcal Disease; Meningococcal Meningitis
• Intervention / Treatment: Biological: Serogroup B meningococcal vaccine

Detailed Description

Novartis will consider this study a success if, at one month following the second vaccination, the two-sided 95% CI of the ratio of the hSBA GMTs for each of 3 serogroup B reference strains (H44/76, 5/99, and NZ98/254) and the two-sided 95% CI of the ratio of the ELISA GMCs against vaccine antigen 287-953 are contained within the interval (0.5, 2.0).

• Study Type: Interventional
• Enrollment (Actual): 344
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • Queensland
    • Herston, Queensland, Australia, 4029
      • Royal Children's Hospital
    • Kippa-Ring, Queensland, Australia, 4021
      • AusTrials Pty Ltd-Suites 6, 10 & 11, Peninsula Specialist Centre
    • Sherwood, Queensland, Australia, 4075
      • AusTrials Pty Ltd-Suite 5, Level 1, 14 Primrose Street
  • South Australia
    • North Adelaide, South Australia, Australia, 5006
      • Women's and Children's Hospital, 72 King William Road
  • Victoria
    • Melbourne, Victoria, Australia, 3010
      • Murdoch Children's Research Institute-Level 5, 207 Bouverie St-University of Melbourne
  • Western Australia
    • Hamilton Street and Roberts Road-Subiaco, Western Australia, Australia, 6008
      • Telethon Institute for Child Heath Research-cnr
• Canada
  • British Columbia
    • Surrey, British Columbia, Canada, V3R 8P8
      • TASC Research Services, 1-15243 91st Avenue
  • Nova Scotia
    • Truro, Nova Scotia, Canada, B2N 1L2
      • Colchester Regional Hospital Colchester Research Group, 68 Robie Street
  • Ontario
    • Etobicoke, Ontario, Canada, M9V 4B4
      • Albion Finch Medical Centre, 1620 Albion Road, Suite 106
    • Sudbury, Ontario, Canada, P3E 1H5
      • Medicor Research Inc, 359 Riverside, Suite 200
    • Toronto, Ontario, Canada, L3Y 5G8
      • SKDS Research Inc, 221-679 Davis Dr.Newmarket
    • Toronto, Ontario, Canada, M5G 1N8
      • Dr. Hartley Garfield Medicine Professional Corporation, 790 Bay Street, Suite 540
    • Woodstock, Ontario, Canada, N4S 5P5
      • Devonshire Clinical Research INC, 423 Devonshire Ave., Suite 301

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 11 years to 17 years (CHILD)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female subjects (11-17 years of age inclusive) who have given their written assent and whose parents or legal guardians have given written informed consent at the time of enrollment
• who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period)
• in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.

Exclusion Criteria:

• History of any serogroup B meningococcal vaccination
• Current or previous, confirmed or suspected disease caused by N. meningitidis
• Exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment
• Significant acute or chronic infection within the previous 7 days or fever (defined as axillary temperature ≥ 38.0 °C) within the previous day
• Antibiotic use within 3 days (72 hours) prior to enrollment
• Pregnancy or nursing (breastfeeding) mothers
• Females of childbearing age who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry
• Any serious chronic or progressive disease, Known or suspected impairment/alteration of the immune system
• Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days
• History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: MenB Lot 1; MenB vaccine Lot 1: 2 doses administered 1 month apart	Biological: Serogroup B meningococcal vaccine; All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2. A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination
ACTIVE_COMPARATOR: MenB Lot 2; MenB vaccine Lot 2: 2 doses administered 1 month apart	Biological: Serogroup B meningococcal vaccine; All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2. A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains.	Consistency of the immune response of the two lots of rMenB+OMV NZ will be assessed at one month after the second vaccination based on the ratio of the vaccine lot hSBA GMTs for each of three serogroup B reference strains (H44/76, 5/99, and NZ98/254) and based on the ratio of Enzyme-linked Immunosorbent Assay (ELISA) GMCs for vaccine antigen 287-953. The equivalence interval will be (0.5, 2.0).	One month after the second vaccination (day 61)
ELISA Geometric Mean Concentration (GMCs) Against Vaccine Antigen 287-953	The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.	One month after the second vaccination (day 61)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects in Each Lot With hSBA ≥ 1:5	The percentage of subjects in each lot with hSBA ≥ 1:5 at one month after the second vaccination for each of the three reference strains (H44/76, 5/99, and NZ98/254) for each vaccine group	One month after the second vaccination (day 61)
Geometric Mean Ratio (GMR) of GMTs Against Each of N. Meningitidis Serogroup B Reference Strains.	The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after the second vaccination vs baseline).	One month after the second vaccination (day 61)
Geometric Mean Ratio (GMR) of ELISA Geometric Mean Concentration (GMCs) Against Antigen 287-953	The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).	One month after the second vaccination (day 61)
hSBA GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.	The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.	Two weeks after the second vaccination (day 45)
GMRs of GMT Against 3 N. Meningitidis Serogroup B Reference Strains at Day 45.	The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N. meningitidis serogroup B reference strains at two weeks after last vaccination.	Two weeks after the second vaccination (day 45)
Percentage of Subjects With hSBA ≥1:5 Against Each of N. Meningitidis Serogroup B Reference Strains at Day 45.	The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.	Two weeks after the second vaccination (day 45)
ELISA GMCs Against Vaccine Antigen 287-953 at Day 45.	The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.	Two weeks after the second vaccination (day 45)
GMR of ELISA GMCs Against Antigen 287-953 at Day 45.	The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 45 vs baseline).	Two weeks after the second vaccination (day 45)
Number of Subjects Reporting Solicited Local and Systemic Adverse Events (AEs)	Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.	From day 1 to day 7 after any vaccination
Number of Subjects Reporting Unsolicited AEs	Number of subjects reporting any Unsolicited AEs after any vaccination.	From day 1 to day 7 after any vaccination.
Number of Subjects Reporting SAEs and AE Leading to Withdrawal	Number of subjects reporting any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject's withdrawal from the study after any vaccination.	Throughout the study period.

Collaborators and Investigators

• Sponsor: Novartis
• Collaborators: Novartis Vaccines

Publications and helpful links

General Publications

• Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015 Sep 22;33(39):5217-24. doi: 10.1016/j.vaccine.2015.06.103. Epub 2015 Jul 29.

Study record dates

Study Major Dates

• Study Start: August 1, 2011
• Primary Completion (ACTUAL): December 1, 2011
• Study Completion (ACTUAL): December 1, 2011

Study Registration Dates

• First Submitted: August 23, 2011
• First Submitted That Met QC Criteria: August 24, 2011
• First Posted (ESTIMATE): August 25, 2011

Study Record Updates

• Last Update Posted (ESTIMATE): February 20, 2015
• Last Update Submitted That Met QC Criteria: February 3, 2015
• Last Verified: February 1, 2015

More Information

Terms related to this study

• Keywords: Meningococcal Meningitis; adolescents; prevention, vaccination
• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; Infections; Central Nervous System Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Meningitis, Bacterial; Central Nervous System Bacterial Infections; Neisseriaceae Infections; Meningitis, Meningococcal; Meningitis; Meningococcal Infections
• Other Study ID Numbers: V72_41